GSK/XenoPort Prep RLS Candidate For Phase III In Neuropathic Pain

This article was originally published in The Pink Sheet Daily

25 Apr 2007
News

Jessica Merrill @Jessicaemerrill Jessica.merrill@informa.com

Executive Summary

Firms plan to initiate pivotal trials of XP13512 in neuropathic pain this year after releasing positive Phase III data for restless legs syndrome.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS065952

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS065952

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

GSK/XenoPort Prep RLS Candidate For Phase III In Neuropathic Pain

News

Executive Summary

Related Content

GSK/SkyePharma’s Requip XL Has Mid-December Action Date

GSK Extends RLS Franchise With Gabapentin Prodrug Through XenoPort Deal

GSK Extends RLS Franchise With Gabapentin Prodrug Through XenoPort Deal

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert